Vimarsana
Biggest News Aggregation in the World

Page 3 - Cms Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cms Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cms Study Today - Breaking & Trending Today

This is why you need to be careful about your heart after Covid - Vimarsana News

This is why you need to be careful about your heart after Covid

This is why you need to be careful about your heart after Covid - People who had recovered from Covid-19 showed stark increases in 20 cardiovascular problems over the year after infection, US study revealed.

Reduced hospitalisation risk for Omicron patients: US study - Vimarsana News

Reduced hospitalisation risk for Omicron patients: US study

A preliminary US study of nearly 70,000 Covid positive people showed a substantially reduced risk of hospitalisation and death from Omicron even after controlling for growing population immunity levels. According to the paper, people infected with Omicron were half as likely to be hospitalized, 75% less likely to require intensive care, and 90% less likely to die than those infected with the formerly dominant Delta variant.

MGI Workforce Study | TMS Studies - Vimarsana News

MGI Workforce Study | TMS Studies

Explore the Materials Genome Initiative Workforce Study, a free study organized by TMS.

Source: tms.org
Indian doctors affirm study that says first COVID19 vaccine dose boosts mental health - Vimarsana News

Indian doctors affirm study that says first COVID19 vaccine dose boosts mental health

The researchers analyzed 8,003 adults who were, surveyed at regular intervals between March 10, 2020, and March 31, 2021

Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu®) - Vimarsana News

Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu®)

Mumbai (Maharashtra) [India], June 9 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India.

Source: aninews.in